Delcath Systems Inc (DCTH) - Total Liabilities
Based on the latest financial reports, Delcath Systems Inc (DCTH) has total liabilities worth $12.13 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Delcath Systems Inc (DCTH) asset resilience to evaluate the company's liquid asset resilience ratio.
Delcath Systems Inc - Total Liabilities Trend (1999–2025)
This chart illustrates how Delcath Systems Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Delcath Systems Inc total assets.
Delcath Systems Inc Competitors by Total Liabilities
The table below lists competitors of Delcath Systems Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Grupo Traxión S.A.B. de C.V
MX:TRAXIONA
|
Mexico | MX$21.16 Billion |
|
Protec Co. Ltd
KQ:053610
|
Korea | ₩101.04 Billion |
|
Tellgen Corp
SHE:300642
|
China | CN¥539.79 Million |
|
Somalogic Inc
NASDAQ:SLGC
|
USA | $68.31 Million |
|
Yuanbao Inc. American Depositary Shares
NASDAQ:YB
|
USA | $1.71 Billion |
|
Changsha Tongcheng Holdings Co Ltd
SHE:000419
|
China | CN¥1.70 Billion |
|
Einhell Germany AG
F:EIN
|
Germany | €421.72 Million |
Liability Composition Analysis (1999–2025)
This chart breaks down Delcath Systems Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See DCTH equity financing ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 11.24 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.11 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.10 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Delcath Systems Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Delcath Systems Inc (1999–2025)
The table below shows the annual total liabilities of Delcath Systems Inc from 1999 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $12.41 Million | +58.27% |
| 2024-12-31 | $7.84 Million | -65.66% |
| 2023-12-31 | $22.84 Million | -3.73% |
| 2022-12-31 | $23.72 Million | +12.04% |
| 2021-12-31 | $21.17 Million | +68.61% |
| 2020-12-31 | $12.56 Million | -38.95% |
| 2019-12-31 | $20.57 Million | -5.57% |
| 2018-12-31 | $21.78 Million | +165.36% |
| 2017-12-31 | $8.21 Million | -77.65% |
| 2016-12-31 | $36.73 Million | +414.99% |
| 2015-12-31 | $7.13 Million | +26.93% |
| 2014-12-31 | $5.62 Million | -19.71% |
| 2013-12-31 | $7.00 Million | -33.13% |
| 2012-12-31 | $10.46 Million | +14.53% |
| 2011-12-31 | $9.14 Million | -57.50% |
| 2010-12-31 | $21.50 Million | +64.75% |
| 2009-12-31 | $13.05 Million | +1032.89% |
| 2008-12-31 | $1.15 Million | -31.33% |
| 2007-12-31 | $1.68 Million | +150.20% |
| 2006-12-31 | $670.37K | +103.10% |
| 2005-12-31 | $330.07K | -41.54% |
| 2004-12-31 | $564.63K | +117.00% |
| 2003-12-31 | $260.20K | +48.54% |
| 2002-12-31 | $175.17K | -0.52% |
| 2001-12-31 | $176.08K | -82.89% |
| 2000-12-31 | $1.03 Million | +835.38% |
| 1999-12-31 | $110.00K | -- |
About Delcath Systems Inc
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development… Read more